Xiamen Humanity Hospital
Adenocarcinoma treatment cost in China typically includes diagnostics like gastroscopy, which ranges from $100 to $600, and surgical interventions like lung cancer surgery, which runs from $24,500 to $43,500. Radiation therapy for colorectal cancer costs $27,500 to $11,500. Total expenses depend on the cancer stage and hospital tier. Patients can save 50-85% compared to the United States. Top treatment centers are located in Guangzhou, Xiamen, and Shanghai.
Typical Adenocarcinoma Treatment Costs in China
Bookimed Expert Insight: Advanced stage patients find the best value at multidisciplinary facilities like Fuda Cancer Hospital. They offer specialized NanoKnife and cryosurgery for complex cases. For those requiring precision radiotherapy, Xiamen Humanity Hospital provides expert care under senior oncology leadership. Early-stage patients benefit from JCI-accredited centers that ensure international safety standards while maintaining high savings. Multimodel approaches at these tertiary hospitals are most effective for thoracic and abdominal malignancies.
| China | Turkey | Austria | |
| Whipple surgery | from $28,500 | from $16,200 | from $45,000 |
| Uterine Trachelectomy | from $9,800 | from $5,500 | from $14,500 |
| Robotic da Vinci prostatectomy | from $18,800 | from $18,000 | from $20,000 |
| Radiation therapy for colorectal cancer | from $11,500 | from $3,250 | from $12,000 |
| Proton-beam therapy | from $36,500 | from $1,500 | from $80,000 |
Chief physician and professor. Grade 1 Expert at the Cancer Center, West China Hospital, Sichuan University (ranked No. 2 in China). Completed a postdoctoral fellowship in interventional radiology at the Chinese PLA General Hospital. Leads multidisciplinary team (MDT) care for complex tumors. Expert in minimally invasive interventional oncology for liver, lung, and pancreatic cancers.
Accreditations: Council Member, WATA. Member of CACA and CMDA committees on intervention, ablation, radioactive seeds, and pain. In 2023, inaugural director member, Palliative Care Committee, Sichuan MDA. Editorial board member of the Chinese Journal of Interventional Imaging and Therapy. Editorial board member of the Chinese Journal of Pain Medicine.
Leads 2 provincial S&T projects and 2 NSFC projects. Has 40+ papers, with 30+ as first or corresponding author. Highest impact factor: 10.73. Hepatocellular carcinoma (HCC) cohort: TACE + lenvatinib vs TACE + sorafenib. OS 18.97 vs 10.77 months. PFS 10.6 vs 5.4 months. ORR 66.8% vs 33.3%.
Dr. He Weibing is a pioneer of argon-helium cryoablation in China with more than 20 years of frontline practice. He was a founding member of Fuda Cancer Hospital (Guangzhou). He co-founded its Minimally Invasive Tumor Treatment Center and served as Executive Deputy Director. He also helped found the Ablation Group of the China Anti-Cancer Association. He has been the primary operator in more than 10,000 procedures.
He specializes in tumor cryoablation and is proficient in 125I seed brachytherapy, with a focus on liver and lung cancers. He proposed ten argon-helium techniques. Key co-authored data include: lung cryotherapy n=508; NSCLC n=120 (CR 25.5%, PR 41.8%, 6/12/24-month survival 64%/55%/36%); pancreatic cancer n=38 (median survival 12 months). He served on editorial boards in 2008 and 2010. He has been a national trainer for Varian and Boston Scientific since 2001.
Professor Luo Xiaoping is a nationally recognized interventional radiologist and a leading authority in Western China. He began pioneering vascular interventions in the early 1990s. He helped found the Interventional Group at the Second Affiliated Hospital of Chongqing Medical University.
He has completed over 100,000 interventional procedures, including about 4,000 complex cases. His key skills include TACE for hepatocellular carcinoma, Budd–Chiari interventions, TIPS, and single-stage bilateral stenting for hilar biliary obstruction, with success rates near 100%. He has been a master’s supervisor since 2007. He has trained many physicians, guided complex cases at more than 40 major hospitals across Western China, and helped build interventional programs. He has published 32 papers as first or corresponding author (22 CSCD core, 4 Chinese core, 6 CSCD extended).
Professor Xiao Yueyong is Chief Physician in the Department of Radiological Diagnosis at the Chinese PLA General Hospital. He is a leading expert in minimally invasive interventional oncology. He serves as the inaugural President of WATA (2025–). He is President of the International (2020–) and Asian (2012–) Societies of Cryotherapy. He is also Deputy Head of the NHC Expert Group on tumour ablation regulations (2009–).
He has performed over 100,000 CT/MRI‑guided minimally invasive procedures. His work covers chemical ablation, RFA, MWA, cryoablation, and NanoKnife (IRE). He introduced and advanced NanoKnife ablation in China. He led the first national standards for tumour cryoablation and NanoKnife.
Honors include the National Special Contribution Award (Lifetime Honorary). He received First Prize from the Chinese Medicine Education Association (2021). He received two Second Prizes for Military Medical Achievements (2016, 2018) and two Second Prizes from the China Anti‑Cancer Association (2019, 2022). He was named Asian Ablation Master. His research record includes 13 Chinese patents. He is the principal investigator for four NSFC projects and one MOST subject. He has published over 200 papers, with over 110 as first or corresponding author and over 40 in SCI journals. He has led over 10 ablation guidelines or consensus statements.
China offers unique adenocarcinoma treatments including CAR-T therapy for solid tumors and early-access oncolytic viruses. Facilities like Fuda Cancer Hospital specialize in minimally invasive cryoimmunotherapy for advanced stages. These protocols often receive regulatory approval years before Western markets. Patients access specific therapies targeting the Claudin18.2 protein.
Bookimed Expert Insight: China is a hub for late-stage cancer care because facilities like Fuda Cancer Hospital combine over 10 types of minimally invasive therapies. Our data shows hospitals here often manage 1,000,000 patients annually. This high volume allows surgeons to refine techniques like NanoKnife and microwave hyperthermia faster than in lower-volume regions. This practical experience is vital for complex adenocarcinoma cases.
Patient Consensus: Patients note that seeking treatment in China often provides earlier access to experimental therapies through active clinical trials. Many emphasize the importance of consulting both local and international oncologists to verify efficacy data before starting newer immunotherapy combinations.
Traditional Chinese Medicine (TCM) is frequently integrated with standard adenocarcinoma treatments in China to enhance outcomes. This integrated approach combines Western tumor-targeting therapies with TCM's holistic focus. It helps mitigate side effects like nausea or fatigue from chemotherapy while supporting the patient’s immune system through recovery.
Bookimed Expert Insight: Patient data from Jinshazhou Hospital of Guangzhou University of Chinese Medicine reveals a significant trend where advanced technologies like CyberKnife M6 are physically housed within TCM-affiliated institutions. This proximity suggests that integration isn't just a philosophy but a structural reality in China. For around $7,700, patients can access high-precision radiosurgery packages that already include the necessary medical consultations for a combined treatment plan.
Patient Consensus: Patients emphasize that TCM should be a side-by-side support rather than a replacement for surgery or chemotherapy. Many note it is essential to disclose herbal use to oncologists to avoid potential liver metabolism interactions.
Beijing, Shanghai, and Guangzhou are the primary hubs for cancer care in China. These cities host national centers like the Cancer Hospital of the Chinese Academy of Medical Sciences. Facilities often feature Joint Commission International (JCI) accreditation and specialize in advanced therapies like CyberKnife and NanoKnife.
Bookimed Expert Insight: Guangzhou holds a unique position for international patients due to a concentration of minimally invasive technologies. Fuda Cancer Hospital has treated over 30,000 international patients using specialized cryosurgery and NanoKnife protocols. While Beijing centers focus on national research, Guangzhou clinics often provide more accessible high-tech packages. For instance, CyberKnife M6 treatments in the region cost around $7,700 and include transfers and hotel stays.
Patient Consensus: Patients emphasize bringing original pathology slides to avoid diagnostic delays. They note that JCI-accredited facilities provide better English support and more organized care transitions for international visitors.
Foreign patients in China usually pay 100% upfront for adenocarcinoma treatments. Most hospitals require proof of funds for admission. Large payments typically move via wire transfer, Alipay, or WeChat Pay. International health insurance often requires pre-authorization 2 to 4 weeks before arrival.
Bookimed Expert Insight: CyberKnife M6 packages in Guangzhou, costing approximately 56,000 CNY, often exclude hospital stays. Our data shows specialized centers like Fuda Cancer Hospital serve 30,000+ international patients. These JCI-accredited facilities often require separate budgeting for hotel accommodation. Always confirm which services are bundled to avoid payment delays.
Patient Consensus: Patients note that foreign credit cards often fail for large medical bills. They recommend having high-limit bank transfers or local mobile payment apps ready. Many found that international insurers might label certain advanced therapies as experimental, making upfront cash essential.
Chinese hospitals manage international patients through dedicated international departments providing on-site medical interpreters and JCI-accredited coordination services. Logistics often include visa assistance, airport transfers, and digital communication tools like WeChat groups. Integrated packages typically bundle surgical consultations, medication, and local transportation for seamless care.
Bookimed Expert Insight: While top-tier facilities like Fuda Cancer Hospital serve thousands of international patients, logistics vary by city. Packages at Jinshazhou Hospital in Guangzhou often include clinic transfers. However, Xiamen Humanity Hospital serves nearly 1,000,000 patients annually. Choosing high-volume centers ensures streamlined administrative protocols for foreign medical records and faster visa processing.
Patient Consensus: Patients note that doctors often speak fluent English, but nursing staff may not. They recommend setting up digital payment apps and hiring local student fixers to help navigate daily hospital bureaucracy.